Shots: CytoReason reports the initiation of a project with Sanofi by utilizing its cell-centered models and deconvolution techniques to counsel mechanistic insights for each asthma endotype The focus of the […]readmore
Tags : Utilizing
Shots: AstraZeneca will utilize ArcherDX’s personalized assay in P-III MERMAID-1 study assessing the effect of adjuvant treatment with Imfinzi (durvalumab) + CT vs CT as monothx. in ~330 patients with […]readmore
Shots: Dyno to receive upfront, research funding, license fees, clinical, regulatory & sales milestones and royalties on WW sales. The company will also utilize its AI technology & its suite […]readmore
Shots: Dragonfly to receive ~ $47.5M up front, equity investment, development & commercial milestones along with royalties on sales of approved therapies Merck to get an option to license exclusive […]readmore
Shots: Trutino to receive upfront, pre/ clinical milestones, regulatory and commercial milestones along with royalties on sales. Boehringer to get access for Trutino’s ODC platform to develop up to 3 […]readmore
Shots: MappBio collaborates with Aridis Pharmaceuticals to develop mAbs productivity enhanced versions of CHO cell lines utilizing Aridis’s APEX Technology CHO cell lines are developed from Chinese hamster ovary. The […]readmore
Shots: Cyclica to receive up front and milestones on completion of specific objectives. Yuhan will leverage Cyclica’s AI integrated drug discovery platform, Ligand Design and Ligand Express in two separate […]readmore